Teva’s Celiac Drug Becomes First to Block Gluten Damage in Clinical Trial

Alkermes (ALKS) and Teva settled patent litigation over LYBALVI. The agreement resolves all dosage strengths and dismisses the lawsuit. ALKS has a $50 price target and is rated Hold. Spark's AI rates it Neutral, citing weak profitability but solid cash flow and pipeline progress.

Teva Pharmaceutical (TEVA) CEO Richard Francis announced increased revenue targets for innovative medicines, aiming for $6-7B by 2030, up from $5B. Branded products revenue is expected to grow from $1.3B in 2022 to $3.77-3.92B this year, and over $6B by 2030. Free cash flow is projected to exceed $3.5B by 2030, up from $2B this year. The company is shifting focus from generics to biopharma, with four branded drugs now and nine expected by 2030.

Teva Pharmaceutical Industries presented its R&D pipeline, highlighting three first-in-class drugs: ecopipam for Tourette syndrome, TEV-'408 for celiac disease and vitiligo, and duvakitug for IBD. The company projects over $10B in peak sales. Ecopipam, acquired for $700M-$900M, showed significant efficacy in trials and has a PDUFA target date of Q1 2027. TEV-'408 secured $500M in funding. Duvakitug is being developed with Sanofi. (350 characters)

Teva Pharmaceutical Industries [TEVA] aims for $6B–$7B in innovative revenue by 2030, supported by a 10-asset pipeline and annual launches. The strategy focuses on neuroscience and immunology, with clinical and commercial catalysts expected. These targets were presented during the company's R&D Day.

Teva Pharmaceutical (TEVA) held its first R&D Day, outlining plans to generate $6–7B in innovative medicines revenue by 2030. The company highlighted its pipeline, including anti-IL-15, anti-PD-1/IL-2, and next-gen antibodies, and reported doubling revenue from innovative medicines since 2023. Teva aims for mid-single-digit total revenue growth and $3.5B+ free cash flow by 2030.

Teva Pharmaceutical Industries (TEVA) aims for $6–7B in innovative medicines revenue by 2030, more than doubling its 2023 figure. The company also reported over $6B in free cash flow from 2023 to 2025, without providing prior-period comparisons.